Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement Proceeds Will Fund Working Capital of the Company LOS ANGELES, Nov. 16 /PRNewswire-FirstCall/ -- Cardo Medical, Inc. (OTC Bulletin Board: CDOM), an

Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement

Proceeds Will Fund Working Capital of the Company

LOS ANGELES, Nov. 16 /PRNewswire-FirstCall/ -- Cardo Medical, Inc. (OTC Bulletin Board: CDOM), an

orthopedic medical device company based in Beverly Hills, California, announced today that it has completed the previously disclosed

private placement transaction in which it successfully raised approximately $6.2 million in gross proceeds through the sale of common

Cardo Medical, Inc. intends to use the proceeds for working capital, general corporate purposes and research and development,

including the integration of its recent acquisitions and the release of its total knee system.

Andrew Brooks, M.D, Chairman and CEO of Cardo Medical stated, "We are pleased to have completed this placement, particularly

with the strong quality of institutional investors who participated. We expect to achieve significant growth in 2010 powered by our recent

acquisitions and the staged release of our Total Knee and Hip Systems over the coming quarters."

Phillip Frost, M.D., former Chairman and founder of IVAX pharmaceuticals stated, "I continue to be impressed by Cardo Medical's

accomplishments during the last 12 months, and toward that end have increased my investment in the company through participation in

this round to help accelerate the company's growth trajectory. I am excited to help build a world class orthopedic medical device

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex: LTS), acted as

the exclusive placement agent for this transaction.

About Cardo Medical, Inc.

Cardo Medical (OTCBB:CDOM) develops reconstructive orthopedic and spinal surgery products through advanced

engineering and focuses on product development, marketing and distribution within the US market. Cardo Medical's superior

engineering talent closely collaborates with leading surgeons around the country to create products that reduce or eliminate joint pain

and allow patients to achieve more active lives. The company's cutting edge products are specifically developed with patients, surgeons

and OR staff in mind and are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery

time and improve outcomes. Cardo Medical's product portfolio includes devices for knee, hip, spinal fusion and motion preservation

arthroplasty and replacement, many of which have already received FDA clearance. Cardo Medical has a robust and innovative product

pipeline pending both USPTO and FDA submission and clearance.

Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to

launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at

www.cardomedical.com for more information on our

complete portfolio of Reconstructive and Spinal Implant systems.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act

of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions

regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual

activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include

those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and

obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any

products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would

support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking

statements also may be adversely affected by general market factors, competitive product development, product availability, federal

and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise,

patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We

intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.